lactic acid and Neointima

lactic acid has been researched along with Neointima in 16 studies

Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.

Neointima: The new and thickened layer of scar tissue that forms on a PROSTHESIS, or as a result of vessel injury especially following ANGIOPLASTY or stent placement.

Research

Studies (16)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

% of Acutely Covered Struts

(NCT00856856)
Timeframe: 2 years

% of Acutely Covered Struts

(NCT00856856)
Timeframe: 3 years

% of Covered Struts (150 µm)

(NCT00856856)
Timeframe: 1 year

% of Uncovered Struts (150 µm)

(NCT00856856)
Timeframe: 1 year

% of Uncovered Struts (150 µm)

(NCT00856856)
Timeframe: 2 years

% of Uncovered Struts (150 µm)

(NCT00856856)
Timeframe: 3 years

Aneurysm

An abnormal expansion or protrusion of a coronary blood vessel resulting from a disease or weakening of the vessel's wall (all three layers) that exceeds the RVD of the vessel by 1.5 times. (NCT00856856)
Timeframe: 1 year

Aneurysm

An abnormal expansion or protrusion of a coronary blood vessel resulting from a disease or weakening of the vessel's wall (all three layers) that exceeds the RVD of the vessel by 1.5 times. (NCT00856856)
Timeframe: 180 days

Aneurysm

An abnormal expansion or protrusion of a coronary blood vessel resulting from a disease or weakening of the vessel's wall (all three layers) that exceeds the RVD of the vessel by 1.5 times. (NCT00856856)
Timeframe: 2 years

Aneurysm

An abnormal expansion or protrusion of a coronary blood vessel resulting from a disease or weakening of the vessel's wall (all three layers) that exceeds the RVD of the vessel by 1.5 times. (NCT00856856)
Timeframe: 3 years

Aneurysm

An abnormal expansion or protrusion of a coronary blood vessel resulting from a disease or weakening of the vessel's wall (all three layers) that exceeds the RVD of the vessel by 1.5 times. (NCT00856856)
Timeframe: 5 years

Cardiac Death

"Cardiac death is defined as any death in which a cardiac cause cannot be excluded.~(This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality, cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)" (NCT00856856)
Timeframe: 1 year

Cardiac Death

"Cardiac death is defined as any death in which a cardiac cause cannot be excluded.~(This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality, cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)" (NCT00856856)
Timeframe: 2 years

Cardiac Death

"Cardiac death is defined as any death in which a cardiac cause cannot be excluded.~(This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality, cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)" (NCT00856856)
Timeframe: 3 years

Cardiac Death

"Cardiac death is defined as any death in which a cardiac cause cannot be excluded.~(This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality, cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)" (NCT00856856)
Timeframe: 30 days

Cardiac Death

"Cardiac death is defined as any death in which a cardiac cause cannot be excluded.~(This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality, cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)" (NCT00856856)
Timeframe: 4 years

Cardiac Death

"Cardiac death is defined as any death in which a cardiac cause cannot be excluded.~(This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality, cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)" (NCT00856856)
Timeframe: 5 years

Clinical Device Success (Per Lesion)

Successful delivery and deployment of the Clinical Investigation scaffold at the intended target lesion and successful withdrawal of the scaffold delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable). Standard pre-dilation catheters and post-dilatation catheters (if applicable) may be used. Bailout patients will be included as device success only if the above criteria for clinical device are met. (NCT00856856)
Timeframe: On day 0 (the day of procedure)

Clinical Procedure Success (Per Patient)

Successful delivery and deployment of the Clinical Investigation scaffold at the intended target lesion and successful withdrawal of the scaffold delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable) and/or using any adjunctive device without the occurrence of ischemia-driven major adverse cardiac event (MACE) during the hospital stay with a maximum of first seven days post index procedure. (NCT00856856)
Timeframe: On day 0 (the day of procedure)

Distal Late Loss: Distal MLD Post-procedure - Distal MLD at 1 Year

Distal Late Loss: distal MLD post-procedure - distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to scaffold placement). (NCT00856856)
Timeframe: 1 year

Distal Late Loss: Distal MLD Post-procedure - Distal MLD at 180 Days

Distal Late Loss: distal MLD post-procedure - distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to scaffold placement). (NCT00856856)
Timeframe: 180 days

Distal Late Loss: Distal MLD Post-procedure - Distal MLD at 2 Years

Distal Late Loss: distal MLD post-procedure - distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to scaffold placement). (NCT00856856)
Timeframe: 2 years

Distal Late Loss: Distal MLD Post-procedure - Distal MLD at 3 Years

Distal Late Loss: distal MLD post-procedure - distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to scaffold placement). (NCT00856856)
Timeframe: 3 years

Distal Late Loss: Distal MLD Post-procedure - Distal MLD at 5 Years

Distal Late Loss: distal MLD post-procedure - distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to scaffold placement). (NCT00856856)
Timeframe: 5 years

Hierarchical Major Adverse Cardiac Event (MACE)

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction,and clinically indicated target lesion revascularization (CI-TLR). (NCT00856856)
Timeframe: 1 year

Hierarchical Major Adverse Cardiac Event (MACE)

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction,and clinically indicated target lesion revascularization (CI-TLR). (NCT00856856)
Timeframe: 180 days

Hierarchical Major Adverse Cardiac Event (MACE)

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction,and clinically indicated target lesion revascularization (CI-TLR). (NCT00856856)
Timeframe: 2 years

Hierarchical Major Adverse Cardiac Event (MACE)

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction,and clinically indicated target lesion revascularization (CI-TLR). (NCT00856856)
Timeframe: 270 days

Hierarchical Major Adverse Cardiac Event (MACE)

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction,and clinically indicated target lesion revascularization (CI-TLR). (NCT00856856)
Timeframe: 3 years

Hierarchical Major Adverse Cardiac Event (MACE)

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction,and clinically indicated target lesion revascularization (CI-TLR). (NCT00856856)
Timeframe: 30 days

Hierarchical Major Adverse Cardiac Event (MACE)

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction,and clinically indicated target lesion revascularization (CI-TLR). (NCT00856856)
Timeframe: 4 years

Hierarchical Major Adverse Cardiac Event (MACE)

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction,and clinically indicated target lesion revascularization (CI-TLR). (NCT00856856)
Timeframe: 5 years

Hierarchical Target Vessel Failure (TVF)

Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT00856856)
Timeframe: 1 year

Hierarchical Target Vessel Failure (TVF)

Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT00856856)
Timeframe: 180 days

Hierarchical Target Vessel Failure (TVF)

Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT00856856)
Timeframe: 2 years

Hierarchical Target Vessel Failure (TVF)

Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT00856856)
Timeframe: 270 days

Hierarchical Target Vessel Failure (TVF)

Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT00856856)
Timeframe: 3 years

Hierarchical Target Vessel Failure (TVF)

Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT00856856)
Timeframe: 30 days

Hierarchical Target Vessel Failure (TVF)

Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT00856856)
Timeframe: 4 years

Hierarchical Target Vessel Failure (TVF)

Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT00856856)
Timeframe: 5 years

In-scaffold Angiographic Binary Restenosis (ABR)

Percent of patients with a followup percent diameter stenosis of >=50% per QCA. (NCT00856856)
Timeframe: 1 year

In-scaffold Angiographic Binary Restenosis (ABR)

Percent of patients with a followup percent diameter stenosis of >=50% per QCA. (NCT00856856)
Timeframe: 180 days

In-scaffold Angiographic Binary Restenosis (ABR)

Percent of patients with a followup percent diameter stenosis of >=50% per QCA. (NCT00856856)
Timeframe: 2 years

In-scaffold Angiographic Binary Restenosis (ABR)

Percent of patients with a followup percent diameter stenosis of >=50% per QCA. (NCT00856856)
Timeframe: 3 years

In-scaffold Angiographic Binary Restenosis (ABR)

Percent of patients with a followup percent diameter stenosis of >=50% per QCA. (NCT00856856)
Timeframe: 5 years

In-scaffold Late Loss (LL): In-scaffold MLD Post-procedure - In-scaffold MLD at 2 Years

In-scaffold Late Loss: in-scaffold MLD post-procedure - in-scaffold MLD at follow-up. (NCT00856856)
Timeframe: 2 years

In-scaffold Late Loss (LL): In-scaffold MLD Post-procedure - In-scaffold MLD at 3 Years

In-scaffold Late Loss: in-scaffold MLD post-procedure - in-scaffold MLD at follow-up. (NCT00856856)
Timeframe: 3 years

In-scaffold Late Loss (LL): In-scaffold MLD Post-procedure - In-scaffold MLD at 5 Years

In-scaffold Late Loss: in-scaffold MLD post-procedure - in-scaffold MLD at follow-up. (NCT00856856)
Timeframe: 5 years

In-scaffold Late Loss: In-scaffold MLD Post-procedure - In-scaffold MLD at 1 Year

In-scaffold Late Loss: in-scaffold MLD post-procedure - in-scaffold MLD at follow-up (NCT00856856)
Timeframe: 1 year

In-scaffold Late Loss: In-scaffold MLD Post-procedure - In-scaffold MLD at 180 Days

In-scaffold Late Loss: in-scaffold MLD post-procedure - in-scaffold MLD at follow-up. (NCT00856856)
Timeframe: 180 days

In-scaffold Percent Diameter Stenosis (%DS)

Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00856856)
Timeframe: 1 year

In-scaffold Percent Diameter Stenosis (%DS)

Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00856856)
Timeframe: 180 days

In-scaffold Percent Diameter Stenosis (%DS)

Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00856856)
Timeframe: 2 years

In-scaffold Percent Diameter Stenosis (%DS)

Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00856856)
Timeframe: 3 years

In-scaffold Percent Diameter Stenosis (%DS)

Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00856856)
Timeframe: 5 years

Ischemia Driven Target Lesion Revascularization (ID-TLR)

"ID-TLR is defined as the revascularization at the target lesion associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target lesion with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 1 year

Ischemia Driven Target Lesion Revascularization (ID-TLR)

"ID-TLR is defined as the revascularization at the target lesion associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target lesion with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 180 days

Ischemia Driven Target Lesion Revascularization (ID-TLR)

"ID-TLR is defined as the revascularization at the target lesion associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target lesion with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 2 years

Ischemia Driven Target Lesion Revascularization (ID-TLR)

"ID-TLR is defined as the revascularization at the target lesion associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target lesion with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 270 days

Ischemia Driven Target Lesion Revascularization (ID-TLR)

"ID-TLR is defined as the revascularization at the target lesion associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target lesion with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 3 years

Ischemia Driven Target Lesion Revascularization (ID-TLR)

"ID-TLR is defined as the revascularization at the target lesion associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target lesion with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 30 days

Ischemia Driven Target Lesion Revascularization (ID-TLR)

"ID-TLR is defined as the revascularization at the target lesion associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target lesion with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 4 years

Ischemia Driven Target Lesion Revascularization (ID-TLR)

"ID-TLR is defined as the revascularization at the target lesion associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target lesion with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 5 years

Ischemia Driven Target Vessel Revascularization (ID-TVR)

"ID-TVR is the revascularization in the target vessel associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target vessel with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 1 year

Ischemia Driven Target Vessel Revascularization (ID-TVR)

"ID-TVR is the revascularization in the target vessel associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target vessel with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 180 days

Ischemia Driven Target Vessel Revascularization (ID-TVR)

"ID-TVR is the revascularization in the target vessel associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target vessel with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 2 years

Ischemia Driven Target Vessel Revascularization (ID-TVR)

"ID-TVR is the revascularization in the target vessel associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target vessel with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 270 days

Ischemia Driven Target Vessel Revascularization (ID-TVR)

"ID-TVR is the revascularization in the target vessel associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target vessel with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 3 years

Ischemia Driven Target Vessel Revascularization (ID-TVR)

"ID-TVR is the revascularization in the target vessel associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target vessel with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 30 days

Ischemia Driven Target Vessel Revascularization (ID-TVR)

"ID-TVR is the revascularization in the target vessel associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target vessel with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 4 years

Ischemia Driven Target Vessel Revascularization (ID-TVR)

"ID-TVR is the revascularization in the target vessel associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target vessel with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 5 years

Late Incomplete Apposition

"Late-Acquired Incomplete Apposition is defined as incomplete apposition of the scaffold at follow-up, which was not present post-procedure.~Incomplete Apposition: Failure of the scaffold to completely appose to the vessel wall after placement is defined as one or more scaffold strut separated from the vessel wall with evidence of blood speckles behind the strut in the ultrasound image." (NCT00856856)
Timeframe: 1 year

Late Incomplete Apposition

"Late-Acquired Incomplete Apposition is defined as incomplete apposition of the scaffold at follow-up, which was not present post-procedure.~Incomplete Apposition: Failure of the scaffold to completely appose to the vessel wall after placement is defined as one or more scaffold strut separated from the vessel wall with evidence of blood speckles behind the strut in the ultrasound image." (NCT00856856)
Timeframe: 180 days

Late Incomplete Apposition

"Late-Acquired Incomplete Apposition is defined as incomplete apposition of the scaffold at follow-up, which was not present post-procedure.~Incomplete Apposition: Failure of the scaffold to completely appose to the vessel wall after placement is defined as one or more scaffold strut separated from the vessel wall with evidence of blood speckles behind the strut in the ultrasound image." (NCT00856856)
Timeframe: 2 year

Late Incomplete Apposition

"Late-Acquired Incomplete Apposition is defined as incomplete apposition of the scaffold at follow-up, which was not present post-procedure.~Incomplete Apposition: Failure of the scaffold to completely appose to the vessel wall after placement is defined as one or more scaffold strut separated from the vessel wall with evidence of blood speckles behind the strut in the ultrasound image." (NCT00856856)
Timeframe: 3 year

Luminal Volume

(NCT00856856)
Timeframe: 1 year

Luminal Volume

(NCT00856856)
Timeframe: 2 years

Luminal Volume

(NCT00856856)
Timeframe: 3 years

Luminal Volume

(NCT00856856)
Timeframe: 5 years

Mean Flow Area

(NCT00856856)
Timeframe: 1 year

Mean Flow Area

(NCT00856856)
Timeframe: 2 years

Mean Flow Area

(NCT00856856)
Timeframe: 3 years

Mean Flow Area

(NCT00856856)
Timeframe: 5 years

Mean Luminal Area

(NCT00856856)
Timeframe: 1 year

Mean Luminal Area

(NCT00856856)
Timeframe: 2 years

Mean Luminal Area

(NCT00856856)
Timeframe: 3 years

Mean Luminal Area

(NCT00856856)
Timeframe: 5 years

Mean Luminal Diameter

(NCT00856856)
Timeframe: 1 year

Mean Luminal Diameter

(NCT00856856)
Timeframe: 2 years

Mean Luminal Diameter

(NCT00856856)
Timeframe: 3 years

Mean Luminal Diameter

It is measured during QCA by the Angiographic Core Lab. (NCT00856856)
Timeframe: 5 years

Mean Reference Area

(NCT00856856)
Timeframe: 1 year

Mean Reference Area

(NCT00856856)
Timeframe: 2 years

Mean Reference Area

(NCT00856856)
Timeframe: 3 years

Mean Reference Area

(NCT00856856)
Timeframe: 5 years

Mean Scaffold Area

(NCT00856856)
Timeframe: 2 years

Mean Scaffold Area

(NCT00856856)
Timeframe: 3 years

Mean Scaffold Diameter

(NCT00856856)
Timeframe: 2 years

Mean Scaffold Diameter

(NCT00856856)
Timeframe: 3 years

Mean Stent Area

(NCT00856856)
Timeframe: 1 year

Mean Stent Diameter

(NCT00856856)
Timeframe: 1 year

Mean Strut Core Area

(NCT00856856)
Timeframe: 1 year

Mean Strut Core Area

(NCT00856856)
Timeframe: 2 years

Mean Strut Core Area

(NCT00856856)
Timeframe: 3 years

Minimum Flow Area

(NCT00856856)
Timeframe: 1 year

Minimum Flow Area

(NCT00856856)
Timeframe: 2 years

Minimum Flow Area

(NCT00856856)
Timeframe: 3 years

Minimum Flow Area

(NCT00856856)
Timeframe: 5 years

Minimum Luminal Area

(NCT00856856)
Timeframe: 1 year

Minimum Luminal Area

(NCT00856856)
Timeframe: 2 years

Minimum Luminal Area

(NCT00856856)
Timeframe: 3 years

Minimum Luminal Area

(NCT00856856)
Timeframe: 5 years

Minimum Luminal Diameter

The average of two orthogonal views (when possible) of the narrowest point within the area of assessment - in lesion, in scaffold or in segment. MLD is visually estimated during angiography by the Investigator; it is measured during QCA by the Angiographic Core Lab. (NCT00856856)
Timeframe: 2 years

Minimum Luminal Diameter

The average of two orthogonal views (when possible) of the narrowest point within the area of assessment - in lesion, in scaffold or in segment. MLD is visually estimated during angiography by the Investigator; it is measured during QCA by the Angiographic Core Lab. (NCT00856856)
Timeframe: 3 years

Minimum Luminal Diameter

The average of two orthogonal views (when possible) of the narrowest point within the area of assessment - in lesion, in scaffold or in segment. MLD is visually estimated during angiography by the Investigator; it is measured during QCA by the Angiographic Core Lab. (NCT00856856)
Timeframe: 5 years

Minimum Luminal Diameter (MLD)

The average of two orthogonal views (when possible) of the narrowest point within the area of assessment - in lesion, in scaffold or in segment. MLD is visually estimated during angiography by the Investigator; it is measured during QCA by the Angiographic Core Lab. (NCT00856856)
Timeframe: 1 year

Minimum Scaffold Area

(NCT00856856)
Timeframe: 2 year

Minimum Scaffold Area

(NCT00856856)
Timeframe: 3 years

Minimum Scaffold Diameter

(NCT00856856)
Timeframe: 2 years

Minimum Scaffold Diameter

(NCT00856856)
Timeframe: 3 years

Minimum Stent Area

(NCT00856856)
Timeframe: 1 year

Minimum Stent Diameter

(NCT00856856)
Timeframe: 1 year

Myocardial Infarction

"Myocardial Infarction (MI):~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT00856856)
Timeframe: 1 year

Myocardial Infarction

"Myocardial Infarction (MI):~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT00856856)
Timeframe: 2 years

Myocardial Infarction

"Myocardial Infarction (MI):~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT00856856)
Timeframe: 3 years

Myocardial Infarction

"Myocardial Infarction (MI):~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT00856856)
Timeframe: 4 years

Myocardial Infarction

"Myocardial Infarction (MI):~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT00856856)
Timeframe: 5 years

Myocardial Infarction

"Myocardial Infarction (MI):~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of Creatine kinase (CK) levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT00856856)
Timeframe: 30 days

Number of Struts in Side Branch

(NCT00856856)
Timeframe: 1 year

Number of Struts in Side Branch

(NCT00856856)
Timeframe: 2 years

Number of Struts in Side Branch

(NCT00856856)
Timeframe: 3 years

Number of Struts in Side Branch

(NCT00856856)
Timeframe: 5 years

Number of Struts Per BVS

(NCT00856856)
Timeframe: 1 year

Number of Struts Per BVS

(NCT00856856)
Timeframe: 2 years

Number of Struts Per BVS

(NCT00856856)
Timeframe: 3 years

Number of Struts Per BVS

(NCT00856856)
Timeframe: 5 years

Percent (%) Lumen Area Stenosis

(NCT00856856)
Timeframe: 1 year

Percent (%) Lumen Area Stenosis

(NCT00856856)
Timeframe: 2 years

Percent (%) Lumen Area Stenosis

(NCT00856856)
Timeframe: 3 years

Percent (%) Lumen Area Stenosis

(NCT00856856)
Timeframe: 5 years

Persisting Dissection

Dissection at follow-up that was present post-procedure. (NCT00856856)
Timeframe: 1 year

Persisting Dissection

Dissection at follow-up that was present post-procedure. (NCT00856856)
Timeframe: 180 days

Persisting Dissection

Dissection at follow-up that was present post-procedure. (NCT00856856)
Timeframe: 2 years

Persisting Dissection

Dissection at follow-up that was present post-procedure. (NCT00856856)
Timeframe: 3 years

Persisting Dissection

Dissection at follow-up that was present post-procedure. (NCT00856856)
Timeframe: 5 years

Persisting Incomplete Apposition

"Persisting incomplete apposition is defined as incomplete apposition at follow-up that was present post-procedure.~Incomplete Apposition: Failure of the scaffold to completely appose to the vessel wall after placement is defined as one or more scaffold strut separated from the vessel wall with evidence of blood speckles behind the strut in the ultrasound image." (NCT00856856)
Timeframe: 1 year

Persisting Incomplete Apposition

"Persisting incomplete apposition is defined as incomplete apposition at follow-up that was present post-procedure.~Incomplete Apposition: Failure of the scaffold to completely appose to the vessel wall after placement is defined as one or more scaffold strut separated from the vessel wall with evidence of blood speckles behind the strut in the ultrasound image." (NCT00856856)
Timeframe: 180 days

Persisting Incomplete Apposition

"Persisting incomplete apposition is defined as incomplete apposition at follow-up that was present post-procedure.~Incomplete Apposition: Failure of the scaffold to completely appose to the vessel wall after placement is defined as one or more scaffold strut separated from the vessel wall with evidence of blood speckles behind the strut in the ultrasound image." (NCT00856856)
Timeframe: 2 year

Persisting Incomplete Apposition

"Persisting incomplete apposition is defined as incomplete apposition at follow-up that was present post-procedure.~Incomplete Apposition: Failure of the scaffold to completely appose to the vessel wall after placement is defined as one or more scaffold strut separated from the vessel wall with evidence of blood speckles behind the strut in the ultrasound image." (NCT00856856)
Timeframe: 3 year

Proximal Late Loss: Proximal MLD Post-procedure - Proximal MLD at 1 Year

Proximal Late Loss: proximal MLD post-procedure - proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to scaffold placement). (NCT00856856)
Timeframe: 1 year

Proximal Late Loss: Proximal MLD Post-procedure - Proximal MLD at 180 Days

Proximal Late Loss: proximal MLD post-procedure - proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to scaffold placement). (NCT00856856)
Timeframe: 180 days

Proximal Late Loss: Proximal MLD Post-procedure - Proximal MLD at 2 Years

Proximal Late Loss: proximal MLD post-procedure - proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to scaffold placement). (NCT00856856)
Timeframe: 2 years

Proximal Late Loss: Proximal MLD Post-procedure - Proximal MLD at 3 Years

Proximal Late Loss: proximal MLD post-procedure - proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to scaffold placement). (NCT00856856)
Timeframe: 3 years

Proximal Late Loss: Proximal MLD Post-procedure - Proximal MLD at 5 Years

Proximal Late Loss: proximal MLD post-procedure - proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to scaffold placement). (NCT00856856)
Timeframe: 5 years

Scaffold Thrombosis

"Scaffold thrombosis will be categorized as acute (≤ 1day), subacute (>1day ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of scaffold thrombosis (angiographic appearance of thrombus within or adjacent to a previously treated target lesion)~In the absence of angiography, any unexplained death, or acute MI (ST segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific ST /T changes and cardiac enzyme elevations do not suffice)~Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00856856)
Timeframe: 1 year

Scaffold Thrombosis

"Scaffold thrombosis will be categorized as acute (≤ 1day), subacute (>1day ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of scaffold thrombosis (angiographic appearance of thrombus within or adjacent to a previously treated target lesion)~In the absence of angiography, any unexplained death, or acute MI (ST segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific ST /T changes and cardiac enzyme elevations do not suffice)~Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00856856)
Timeframe: 2 years

Scaffold Thrombosis

"Scaffold thrombosis will be categorized as acute (≤ 1day), subacute (>1day ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of scaffold thrombosis (angiographic appearance of thrombus within or adjacent to a previously treated target lesion)~In the absence of angiography, any unexplained death, or acute MI (ST segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific ST /T changes and cardiac enzyme elevations do not suffice)~Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00856856)
Timeframe: 3 years

Scaffold Thrombosis

"Scaffold thrombosis will be categorized as acute (≤ 1day), subacute (>1day ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of scaffold thrombosis (angiographic appearance of thrombus within or adjacent to a previously treated target lesion)~In the absence of angiography, any unexplained death, or acute MI (ST segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific ST /T changes and cardiac enzyme elevations do not suffice)~Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00856856)
Timeframe: 30 days

Scaffold Thrombosis

"Scaffold thrombosis will be categorized as acute (≤ 1day), subacute (>1day ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of scaffold thrombosis (angiographic appearance of thrombus within or adjacent to a previously treated target lesion)~In the absence of angiography, any unexplained death, or acute MI (ST segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific ST /T changes and cardiac enzyme elevations do not suffice)~Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00856856)
Timeframe: 4 years

Scaffold Thrombosis

"Scaffold thrombosis will be categorized as acute (≤ 1day), subacute (>1day ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of scaffold thrombosis (angiographic appearance of thrombus within or adjacent to a previously treated target lesion)~In the absence of angiography, any unexplained death, or acute MI (ST segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific ST /T changes and cardiac enzyme elevations do not suffice)~Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00856856)
Timeframe: 5 years

Scaffold Volume

(NCT00856856)
Timeframe: 2 years

Scaffold Volume

(NCT00856856)
Timeframe: 3 years

Stent Volume

(NCT00856856)
Timeframe: 1 year

Strut Volume

(NCT00856856)
Timeframe: 1 year

Strut Volume

(NCT00856856)
Timeframe: 2 years

Strut Volume

(NCT00856856)
Timeframe: 3 years

Thrombus

(NCT00856856)
Timeframe: 1 year

Thrombus

(NCT00856856)
Timeframe: 180 days

Thrombus

(NCT00856856)
Timeframe: 2 years

Thrombus

(NCT00856856)
Timeframe: 3 years

Thrombus

(NCT00856856)
Timeframe: 5 years

Tissue Coverage Area BVS (Neointimal Area)

(NCT00856856)
Timeframe: 1 year

Tissue Coverage Area BVS (Neointimal Area)

(NCT00856856)
Timeframe: 2 years

Tissue Coverage Area BVS (Neointimal Area)

(NCT00856856)
Timeframe: 3 years

Tissue Coverage Area Classical

(NCT00856856)
Timeframe: 1 year

Tissue Coverage Area Classical

(NCT00856856)
Timeframe: 2 years

Tissue Coverage Area Classical

(NCT00856856)
Timeframe: 3 years

Tissue Coverage Obstruction Volume BVS

(NCT00856856)
Timeframe: 1 year

Tissue Coverage Obstruction Volume BVS

(NCT00856856)
Timeframe: 2 years

Tissue Coverage Obstruction Volume BVS

(NCT00856856)
Timeframe: 3 years

Tissue Coverage Obstruction Volume Classical

(NCT00856856)
Timeframe: 1 year

Tissue Coverage Obstruction Volume Classical

(NCT00856856)
Timeframe: 2 years

Tissue Coverage Obstruction Volume Classical

(NCT00856856)
Timeframe: 3 years

Tissue Coverage Volume BVS

(NCT00856856)
Timeframe: 1 year

Tissue Coverage Volume BVS

(NCT00856856)
Timeframe: 2 years

Tissue Coverage Volume BVS

(NCT00856856)
Timeframe: 3 years

Tissue Coverage Volume Classical

(NCT00856856)
Timeframe: 1 year

Tissue Coverage Volume Classical

(NCT00856856)
Timeframe: 2 years

Tissue Coverage Volume Classical

(NCT00856856)
Timeframe: 3 years

Volume Obstruction (VO)

Defined as scaffold intimal hyperplasia and calculated as 100*(Scaffold Volume - Lumen Volume)/Scaffold Volume by IVUS. (NCT00856856)
Timeframe: 1 year

Volume Obstruction (VO)

Defined as scaffold intimal hyperplasia and calculated as 100*(Scaffold Volume - Lumen Volume)/Scaffold Volume by IVUS. (NCT00856856)
Timeframe: 180 days

Volume Obstruction (VO)

Defined as scaffold intimal hyperplasia and calculated as 100*(Scaffold Volume - Lumen Volume)/Scaffold Volume by IVUS. (NCT00856856)
Timeframe: 2 year

Volume Obstruction (VO)

Defined as scaffold intimal hyperplasia and calculated as 100*(Scaffold Volume - Lumen Volume)/Scaffold Volume by IVUS. (NCT00856856)
Timeframe: 3 year

Vasomotion Analysis: In-scaffold Mean Luminal Diameter

Vasomotion function was assessed in reaction to nitrate administration. (NCT00856856)
Timeframe: 5 years

Trials

1 trial available for lactic acid and Neointima

Other Studies

15 other studies available for lactic acid and Neointima